Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Aquinox and Neoleukin merge to develop immunotherapies

Executive Summary

Public Vancouver-based biotech Aquinox Pharmaceuticals Inc. acquired Neoleukin Therapeutics Inc. (de novo protein design technology for cancer drug development) in a reverse merger through which Aquinox will assume the Neoleukin name and Neoleukin’s executive staff.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
Deal Status
  • Final
Deal Type
  • Acquisition
    • Acquisition of Private Biotech
    • Full Acquisition
    • Includes Contract
    • Intra-Biotech Deal
    • Payment Includes Stock
    • Reverse Acquisition

Related Companies

UsernamePublicRestriction

Register